Organic Active Ingredients TRIZ Cases

Engineered lysine K222 enables site-specific drug coupling in anti-HER2 antibodies, resolving manufacturing heterogeneity and improving treatment reliability.

SMAC mimetic compounds antagonize cIAP1 and XIAP proteins to induce apoptosis, bypassing resistance from IAP overexpression.

Segmented chromogenic peptides achieve neuroprotection at lower concentrations, reducing adverse effects of high-dose therapies.

In silico tumor models replace lengthy in vitro assays, resolving the conflict between measurement precision and assay duration while maintaining validity.

A dietary composition lowers glycemic load to enhance sleep efficiency and duration.

Cross-linked mucin nanoparticles improve drug bioavailability by leveraging mucoadhesion and lectin targeting to overcome limited absorption.

Modifying rexinoid structures improves solubility and bioavailability while maintaining RXR agonist activity for treating cancers and Alzheimer's disease.

Malic acid creates an acidic microenvironment that maintains pH-independent dissolution of pimobendan despite low aqueous solubility.

Compounds inhibit Smad2/3 phosphorylation to treat fibrotic disease, bypassing undruggable Ras GTP binding domains.

A hyaluronic acid and bone morphogenetic protein composition delivers sustained pain relief through controlled precipitation.

Targeting PDCD4 resolves side effects and population sensitivity issues in antidepressant treatment.

Progenitor cells and secretory supernatants modulate hepatic stellate cell activity to prevent chronic disease progression.

Imidazo[1,5-a]pyrazine derivatives act as selective PI3Kδ inhibitors to reduce infection risk from low PI3Kγ selectivity.

Modifying chemical structure parameters of BH3 mimetics enables adaptation to mutant forms while minimizing side effects.

Annealed freeze-dried polymeric nanoparticles reconstitute within five minutes, resolving the stability versus reconstitution time trade-off.

Formula I compounds resolve the trade-off between therapeutic potency and off-target effects by selectively inhibiting LSD1 to normalize gene expression.

A polyaphron dispersion enhances dermal diffusion of vitamin D analogues through skin layers.

Pteridinone compounds selectively target the EGFR T790M mutation to overcome drug resistance in non-small cell lung cancer.

Formula I compound inhibits IDO and TDO enzymes to resolve limited disease coverage of existing single-target inhibitors.

Self-emulsifying lorazepam eutectic mixtures enable rapid intraoral transmucosal absorption.

Segmented synthesis of 1H-furo[3,2-b]imidazo[4,5-d]pyridine compounds reduces impurities and lowers costs compared to complex prior art methods.

Polyoxazoline aggregates disperse taxanes at hydrophobic domains, resolving poor aqueous solubility and severe side effects.

Pyrrolopyrimidine compounds target viral replication mechanisms to reduce influenza titers, addressing drug resistance and antigenic drift.

Cyclopropano-linked compounds inhibit dUTPase enzyme activity, sensitizing cancer cells to thymidylate synthase inhibitors and overcoming drug resistance.

RXR-gamma agonists upregulate NKG2DL expression to counter immunosurveillance escape caused by ligand downregulation in colorectal cancer.

A methylphenidate carrier system uses a high viscosity liquid matrix to provide sustained drug release kinetics.

A composition combining virus-like particle-packaged cyclic dinucleotides with an anti-CTLA-4 antibody fragment to modulate immune responses.

Compounds of Formula I and II target neuroactive steroid binding sites on the GABA receptor complex, expanding therapeutic scope while reducing side effects.

Combining berberine analogs with JAK inhibitors creates a targeted pharmaceutical composition.

Substituted azole dione compounds inhibit the host protein XPO1, increasing nuclear retention of viral proteins to reduce titers and lower resistance risk.

Torula yeast RNA inhibits the G1 to S phase transition, resolving limited efficacy of salmon milt nucleic acids in early cell cycle stages.

An oral nutritional supplement stimulates pituitary growth hormone release to promote fertility.

Ionic complexes of lactoferrin with acid milk proteins stabilize dispersion in infant formula.

A diphosphate-choline prodrug delivers N4-hydroxycytidine to bypass metabolic conversion steps.

A GPC3-directed antibody-drug conjugate delivers tubulysin M intracellularly via a glucuronide-based linker.

A pharmaceutical composition for otic administration uses a specific polymer to enable sustained drug release in the ear.

Sequential extraction isolates high-yield hyaluronic acid from alligator by-products, replacing inefficient low-recovery animal sourcing.